Tags:DrugPublic
Nevro is focused on becoming a leader in neuromodulation by developing innovative, evidence based solutions. The company pioneered high frequency stimulation for the treatment of chronic pain and other neurological disorders. Nevro’s Senza® system delivers HF10™ therapy, an advanced spinal cord stimulation therapy which provides electrical pulses to the spinal cord at a rate up to 10,000 per second (10 kHz), as compared to traditional low-frequency SCS therapy, which usually deliver the electrical pulses at less than 100 pulses per second for chronic back- and leg-pain. Nevro completed an initial public offering in November 2014.
Total raised: $194.5M

Investors 1

Funding Rounds 2

DateSeriesAmountInvestorsDeal News
13.06.2016-$172.5M--
01.10.2008-$22M--

Mentions in press and media 3

DateTitleDescriptionCategoryAuthorSource
13.06.2016Nevro Anno...Redwood City, CA — Nevro Corp....--baycitycap...
06.06.2016Nevro Anno...Redwood City, CA — Nevro Corp....--baycitycap...
01.10.2008Nevro rais...Nevro Corp. has raised $22 mil...--venturebea...